RxDoctor Payments Data

Chia-Hsuan Lin

Acute Care · Murray, UTNPI 1033884192

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Impulse Dynamics (USA) Inc. at 36.0% of the total. 2025 is the largest year on record at $2,771, more than ten times the $19 reported in 2022. Among acute care clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,392in general payments, 2019–2025

Across 26 payments — averaging $130.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$1K
  • Boston Scientific$1K
  • Abiomed$233
  • Amgen$214
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$144
  • Biosense Webster, Inc.$125
  • plus $280 from 6 others

What the payments were for

  • Travel & lodging$1,67849%
  • Food & beverage$1,71451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,392 in reported general payments places this provider in the 95th percentile of 119 acute care providers in Utah.

See all acute care providers in Utah

Medicare billing

Part B allowed, 2024
$5,105
Medicare patients
40
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$141,092
XareltoRivaroxaban28$41,348
FarxigaDapagliflozin Propanediol24$19,636
JardianceEmpagliflozin15$18,278
Repatha SureclickEvolocumab18$13,257
Flecainide Acetate74$1,824
Metoprolol Succinate111$1,360
Potassium Chloride84$1,244
Diltiazem 24hr ErDiltiazem Hcl38$1,180
Atorvastatin Calcium103$959
Amiodarone Hcl75$893
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$886
Rosuvastatin Calcium67$864
Losartan Potassium107$734
ClopidogrelClopidogrel Bisulfate67$708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$141,092133 claims
AstraZenecaFarxiga$122$19,63624 claims
Boehringer IngelheimJardiance$20$18,27815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 119 acute care providers in Utah.

Other acute care in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →